Werewolf Therapeutics, Inc. - HOWL Net Assets per Single Share

Graphic logo of Werewolf (HOWL)

Werewolf Therapeutics (HOWL) possesses exceptional pricing power due to the uniqueness of its developments. However, business success depends on clinical trial results and partner payments. The book value per share trend captures these financial aspects, with the latest value recorded as 0.34. The company is implementing a targeted cytokine delivery strategy to establish a new safety benchmark in oncology.

HOWL: Werewolf Therapeutics Net Asset Value per Share 07/04/2022 - 10/27/2026

Werewolf Therapeutics Inc. - analytical breakdowns and key metrics (HOWL)

- price and consensus price forecast:
Stock Quotes Werewolf|HOWL - Consensus Target
- market capitalization data:
Market Value Werewolf Therapeutics, Inc.|HOWL - Total Company Value
- book capitalization data:
Net Assets per Single Share Werewolf Therapeutics|HOWL - Total Stockholders' Equity|Market Value to Book Value Ratio werewolftx.com|HOWL - Total Business Assets
- debt and liquidity data:
Total Debt to Capital Werewolf Therapeutics|HOWL - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Werewolf|HOWL - Company Cumulative Debt|Debt to Book Capitalization Ratio Werewolf Therapeutics, Inc.
Fundamental company valuation:HOWL - werewolftx.com
Flagship merchandise of Werewolf

Book value per share reflects the portion of equity attributable to a single security, serving as a fundamental indicator of intrinsic asset value net of liabilities. By analyzing the adjusted book value per share, an investor can observe the capitalization dynamics of Werewolf Therapeutics (HOWL), which in this instance is supported by the inflow of partner tranches and the development of the PREDATOR platform for oncology treatment.

Competitor analysis for Werewolf Therapeutics

IBRX: Accounting Value per Share|IMCR: Accounting Value per Share|Janux Therapeutics (JANX) - Net Assets per Single Share|RCUS (arcusbio.com) - Net Assets per Single Share|Net Assets per Single Share ZYME (Zymeworks)|Net Asset Value per Share TNGX|Net Assets per Single Share Iovance IOVA|Equity per Share Immatics Biotechnologies (IMTX)|Xencor, Inc. - Book Value per Share|compasstherapeutics.com - Accounting Value per Share|REPL (Replimune) - Net Assets per Single Share|LYEL: Net Asset Value per Share|Innate Pharma, S.A. (IPHA) - Net Assets per Single Share|PYXS (Pyxis Oncology) - Net Assets per Single Share|Net Assets per Single Share CGEN (Compugen Ltd)|Net Asset Value per Share iobiotech.com|STRO: Book Value per Share|Book Value of One Share MiNK Therapeutics Inc. INKT|IMMX: Accounting Value per Share|ALXO - Net Asset Value per Share|Accounting Value per Share Cue Biopharma, Inc. (CUE)|PDSB - Accounting Value of a Share|sonnetbio.com - Book Value per Share|MAIA (MAIA Biotech) - Net Assets per Share|Net Assets per Single Share LIMN|Accounting Value per Share LVTX|Net Assets per Single Share NXTC (NextCure, Inc.)|Accounting Value per Share leaptx.com LPTX|Accounting Value per Share INTS (Intensity Therapeutics, Inc.)|Sensei Biotherapeutics Inc - Book Value per Share|Synthetic Biologics (TOVX) - Net Assets per Single Share|GRTS: Equity per Share|Net Assets per Single Share KA|Net Asset Value per Share neximmune.com|Turnstone Biologics Corp - Accounting Value per Share|Book Value of One Share Vaccinex Inc. (VCNX)|Accounting Value per Share Harpoon Tx